Vernakalant

Vernakalant (INN; codenamed RSD1235, proposed tradenames Kynapid and Brinavess) is an investigational drug under regulatory review for the acute conversion of atrial fibrillation. It was initially developed by Cardiome Pharma, and the intravenous formulation was bought for further development by Merck in April 2009. In September 2012, Merck terminated its agreements with Cardiome and has consequently returned all rights of the drug back to Cardiome.